Research stack

Tesamorelin + MOTS-c Mitochondrial Recomposition

GHRH-driven lean-mass support paired with mitochondrial peptide signaling.

Component peptides

A stabilised GHRH analog carrying a trans-3-hexenoyl group at the N-terminus, protecting against dipeptidyl-peptidase-IV cleavage. FDA-approved in 2010 as Egrifta for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

MOTS-c

A 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, characterised in research on mitochondrial signalling, metabolic homeostasis, and exercise biology.

Goal

GHRH-driven lean-mass support paired with mitochondrial peptide signalling.

Peptides

Tesamorelin, MOTS-c

Why it works

GHRH-analog signalling restores pulsatile GH for lean-mass support while MOTS-c activates AMPK to shift mitochondrial energy metabolism toward oxidative capacity.

How to use

Tesamorelin — 2 mg once daily subcutaneous, evening.
MOTS-c — 5-10 mg 2-3x weekly subcutaneous.

Last updated: 2026-09-15

Component peptides	Tesamorelin + MOTS-c
Duration reported	12 weeks
Cycle pattern	12 weeks continuous
Difficulty	advanced
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.